REVB
Revelation Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.01
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 19.8K | 27.1K | 27.9K | 25.0K | 40.0K |
| Gross Profit | (19.8K) | (27.1K) | (27.9K) | (25.0K) | (40.0K) |
| Operating Expenses | |||||
| R&D Expense | 5.2M | 4.1M | 3.5M | 4.1M | 5.4M |
| SG&A Expense | 6.1M | 5.0M | 4.4M | 4.5M | 5.5M |
| General & Admin Expense | 6.1M | 5.0M | 4.4M | 4.5M | 5.5M |
| Selling & Marketing Expense | (7.2K) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.3M | 9.1M | 8.0M | 8.7M | 10.9M |
| Cost and Expenses | 11.3M | 9.1M | 8.0M | 8.7M | 10.9M |
| Operating Income (EBIT) | (11.3M) | (9.1M) | (8.0M) | (8.7M) | (10.9M) |
| Non-Operating | |||||
| Interest Income | 82.2K | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 82.2K | — | — | — | — |
| Other Non-Op Income/Expense | 518.7K | 157.2K | (7.1M) | 8.5M | 35.0K |
| Non-Operating Income (excl Interest) | (338.9K) | — | — | — | — |
| EBT (Pre-Tax Income) | (10.8M) | (8.9M) | (15.0M) | (120.3K) | (10.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (10.8M) | (8.9M) | (15.0M) | (120.3K) | (10.8M) |
| Earnings from Cont. Ops | (10.8M) | (8.9M) | (15.0M) | (120.3K) | (10.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.2M) | (14.9M) | (15.0M) | (120.3K) | (10.8M) |
| Per Share | |||||
| Basic EPS | ($7.00) | ($23.95) | ($87.68) | ($8.41) | ($9,643.37) |
| Diluted EPS | ($7.00) | ($23.95) | ($87.68) | ($8.41) | ($9,643.37) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.8M | 620800 | 171510 | 14290 | 1123 |
| Diluted Shares Outstanding | 3.8M | 620800 | 171510 | 14290 | 1123 |
| Profitability Metrics | |||||
| EBITDA | (10.9M) | (9.0M) | (7.9M) | (8.6M) | (10.8M) |
| D&A | 28.1K | 27.1K | 27.9K | 25.0K | 25.0K |
| EBIT | (10.9M) | (9.1M) | (8.0M) | (8.7M) | (10.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026